Humacyte (NASDAQ: HUMA) back in line with Nasdaq $1.00 bid rule
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Humacyte, Inc. has regained compliance with Nasdaq’s minimum bid price rule. The company had previously been notified that its common stock traded below the required $1.00 per share bid price for 30 consecutive business days ended May 1, 2026.
To cure the issue, Humacyte’s stock needed to close at or above $1.00 for at least 10 consecutive business days before November 2, 2026. On June 5, 2026, Nasdaq informed the company that this condition was met and that its listing on The Nasdaq Global Select Market is now in good standing, with the matter considered closed.
Positive
- Nasdaq compliance restored: Humacyte regained compliance with Nasdaq Listing Rule 5450(a)(1) after its stock closed at or above $1.00 per share for at least 10 consecutive business days, removing an immediate risk to its continued listing on The Nasdaq Global Select Market.
Negative
- None.
Insights
Humacyte removed an immediate delisting risk by regaining Nasdaq bid price compliance.
Humacyte previously fell out of compliance because its common stock traded below the required $1.00 minimum bid price for 30 consecutive business days ended May 1, 2026. Nasdaq granted a grace period running to November 2, 2026 to restore compliance.
The company has now achieved at least 10 consecutive business days with a closing bid at or above $1.00, and Nasdaq has confirmed compliance with Listing Rule 5450(a)(1) and closed the matter. This removes the near-term listing overhang; longer-term trading performance will still depend on the business and market conditions.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Minimum bid price requirement: $1.00 per share
Non-compliance period length: 30 consecutive business days
Cure period trading requirement: 10 consecutive business days
+2 more
5 metrics
Minimum bid price requirement
$1.00 per share
Nasdaq Listing Rule 5450(a)(1) threshold for Humacyte common stock
Non-compliance period length
30 consecutive business days
Bid price below $1.00 ended May 1, 2026
Cure period trading requirement
10 consecutive business days
Days with closing bid at or above $1.00 to regain compliance
Compliance deadline
November 2, 2026
Last day to meet the 10-day $1.00 bid price condition
Compliance confirmation date
June 5, 2026
Nasdaq letter stating Humacyte regained bid price compliance
Key Terms
Nasdaq Listing Rule 5450(a)(1), minimum bid price requirement, The Nasdaq Global Select Market, Emerging growth company
4 terms
Nasdaq Listing Rule 5450(a)(1) regulatory
"the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1)"
Nasdaq Listing Rule 5450(a)(1) is a continued-listing standard that sets a minimum share price companies must maintain to remain listed on the Nasdaq market—commonly a $1.00 per-share threshold. Investors care because falling below that floor can trigger a compliance review and possible delisting, which is like failing a minimum grade and losing access to the public market; delisting can reduce liquidity, visibility and the ability to raise capital.
minimum bid price requirement financial
"it had regained compliance with the $1.00 per share minimum bid price requirement for continued inclusion"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
The Nasdaq Global Select Market market
"for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1)"
Emerging growth company regulatory
"Emerging growth company Item 8.01 Other Events."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What Nasdaq issue did Humacyte (HUMA) face before this 8-K?
Humacyte previously received a Nasdaq notice that its common stock bid price was below the required $1.00 per share for 30 consecutive business days ended May 1, 2026. This triggered a deficiency under Nasdaq Listing Rule 5450(a)(1) and started a compliance grace period.
How did Humacyte regain compliance with Nasdaq’s $1.00 bid price rule?
Humacyte regained compliance by having its common stock close at $1.00 per share or higher for at least 10 consecutive business days. Nasdaq staff confirmed on June 5, 2026, that this condition under Listing Rule 5450(a)(1) was satisfied and closed the matter.
What Nasdaq market is Humacyte’s stock listed on after regaining compliance?
Humacyte’s common stock remains listed on The Nasdaq Global Select Market. After the stock met the minimum $1.00 bid price requirement for the required period, Nasdaq notified the company on June 5, 2026, that compliance was restored and no further listing action was needed regarding this issue.
What was the deadline for Humacyte to fix its Nasdaq bid price deficiency?
Humacyte was given until November 2, 2026, to regain compliance with Nasdaq’s $1.00 minimum bid price rule. Within this window, the company needed its stock to close at or above $1.00 for at least 10 consecutive business days, a condition it met before the deadline.
Does this Nasdaq decision affect Humacyte’s warrants trading under HUMAW?
The filing specifically addresses compliance for Humacyte’s common stock minimum bid price on The Nasdaq Global Select Market. It lists both common stock (HUMA) and redeemable warrants (HUMAW) as registered securities but only discusses the bid price requirement and compliance status for the common stock.